NeuRA has made a 3T MRI scanner available for research since 2003. The current scanner is a Philips 3T TX MRI (upgraded May 2010).
The facility currently operates for research 50% of the time and is open for research to scientists on a merit-based, user pays basis. It supports an active MRI research community of researchers from UNSW, The University of Sydney, Macquarie University and The University of Western Sydney as well as researchers from interstate and international sites as required.
NeuRA researchers are stepping up their research with the introduction of a new perturbation treadmill aimed at preventing falls and improving balance. What is a perturbation treadmill? A perturbation treadmill is a treadmill, like those in the gym, but with two belts instead of one. We can control the speed of each belt independently. Each foot is placed on a […]
We aimed to systematically quantify changes in sexual behavior, including current symptoms and changes from prior diagnoses, in behavioral-variant (bvFTD) and semantic dementia (SD), compared to Alzheimer's disease (AD). Overall loss of affection, reduced initiation of sexual activity, and responsiveness is an overwhelming feature of bvFTD. In contrast, aberrant or unusual sexual behavior is observed in the minority of bvFTD patients. The underlying pathophysiology of these changes likely reflects structural and functional changes in frontoinsular and limbic regions including the hypothalamus.
To contrast the relationships of hormonal eating peptides and hypothalamic volumes to eating behavior and metabolic changes (body mass index [BMI]) in behavioral variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia (svPPA). Eating abnormalities are multifactorial in FTD. In bvFTD, they are in part related to hypothalamic degeneration, with potential disintegration of the network connections between the hypothalamus and orbitofrontal cortex/reward pathways. In svPPA, although hypothalamic volumes are preserved, this group experiences elevated AgRP levels similar to bvFTD, which predicts BMI in both groups. This finding highlights the potential key role of AgRP in eating and metabolic changes and provides a potential target for treatment to modify disease progression.